Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Myoblast-based gene therapies

T A Partridge1, K E Davies

  • 1MRC Clinical Sciences Centre, Royal Postgraduate Medical School, Hammersmith Hospital, London, UK.

British Medical Bulletin
|January 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Syncoilin is an intermediate filament protein in activated hepatic stellate cells.

Histochemistry and cell biology·2013
Same author

Tissue culture of skeletal muscle.

Methods in molecular biology (Clifton, N.J.)·2011
Same author

UTRN on chromosome 6q24 is mutated in multiple tumors.

Oncogene·2007
Same author

Utrophin upregulation in Duchenne muscular dystrophy.

Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology·2006
Same author

A and B utrophin in human muscle and sarcolemmal A-utrophin associated with tumours.

Neuromuscular disorders : NMD·2005
Same author

Regulation of utrophin in transgenic mice.

Neuromuscular disorders : NMD·2005

Gene therapy for skeletal muscle disorders is promising, with methods like myoblast transfer and viral vectors showing potential for gene delivery. However, current techniques are not yet practical for treating genetic muscle diseases.

Area of Science:

  • Biotechnology
  • Molecular Biology
  • Genetics

Background:

  • Recent advances in identifying genetic causes of neuromuscular disorders have spurred interest in gene therapy targeting skeletal muscle.
  • Skeletal muscle's unique properties offer potential for therapeutic gene modification.

Purpose of the Study:

  • To review current methods for altering the genetic makeup of skeletal muscle for therapeutic purposes.
  • To evaluate the feasibility of these gene therapy approaches for treating genetic muscle diseases.

Main Methods:

  • Exploration of gene delivery vectors including myoblasts, DNA expression-plasmids, and recombinant adenoviruses and retroviruses.
  • Assessment of gene expression persistence and genomic integration for each method.

Related Experiment Videos

Main Results:

  • Myoblast transfer, DNA plasmids, and adenoviruses allow gene introduction with persistent expression, but lack genomic integration.
  • Retroviruses integrate genes into dividing myoblasts, offering genomic integration.
  • No current method is a practical solution for genetic muscle disease therapy.

Conclusions:

  • While direct gene therapy for genetic muscle diseases remains challenging, skeletal muscle can be engineered to produce therapeutic non-muscle proteins.
  • Further research is needed to develop practical gene therapy solutions for neuromuscular disorders.